ABLYNX TO PRESENT PROGRESS IN 2011 AND ITS 2012 STRATEGY AT 30TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

GHENT, Belgium, 9 January 2012 - Ablynx [Euronext Brussels: ABLX] today announced that it will present a review of its progress in 2011, together with an outline of the Company's evolving strategy and a review of its portfolio and priorities for 2012, at the 30th Annual J.P. Morgan Healthcare Conference in San Francisco, 9-12 January 2012.
During the course of 2011, Ablynx has made significant progress both commercially and clinically. Cash at the end of 2011 is expected to exceed EUR80M, including EUR12M of the EUR20M upfront fee from the third co-discovery and co-development deal with Merck Serono. During the year, four Phase II clinical trials of Nanobody®-based products were progressed or completed, with one achieving clinical proof-of-concept in a disease population. Five Phase I clinical trials were also further progressed or completed.
During 2012, Ablynx will focus its investments on its more advanced clinical assets, including ALX-0061 (anti-IL-6R) in rheumatoid arthritis (RA), ALX-0081/ALX-0681 (anti-vWF) in thrombotic thrombocytopenic purpura (TTP), ATN-103 (anti-TNF